SPRB logo

Spruce Biosciences (SPRB) Cash From Investing

SPRB Annual CFI

$55.78 M
+$32.09 M+135.43%

31 December 2023

SPRB Cash From Investing Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

SPRB Quarterly CFI

$0.00
$0.000.00%

30 September 2024

SPRB Quarterly CFI Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

SPRB TTM CFI

$9.30 M
-$13.99 M-60.07%

30 September 2024

SPRB TTM CFI Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

SPRB Cash From Investing Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+135.4%-100.0%-83.3%
3 y3 years+10000.0%-100.0%-83.3%
5 y5 years+100.0%-100.0%-83.3%

SPRB Cash From Investing High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+170.4%-100.0%+100.0%-84.8%+110.7%
5 y5-yearat high+170.4%-100.0%+100.0%-84.8%+110.7%
alltimeall timeat high+170.4%-100.0%+100.0%-84.8%+110.7%

Spruce Biosciences Cash From Investing History

DateAnnualQuarterlyTTM
Sept 2024
-
$0.00(0.0%)
$9.30 M(-60.1%)
June 2024
-
$0.00(0.0%)
$23.29 M(-48.6%)
Mar 2024
-
$0.00(-100.0%)
$45.29 M(-18.8%)
Dec 2023
$55.78 M(+135.4%)
$9.30 M(-33.5%)
$55.78 M(-8.6%)
Sept 2023
-
$13.99 M(-36.4%)
$61.05 M(+102.4%)
June 2023
-
$22.00 M(+109.8%)
$30.16 M(-27.6%)
Mar 2023
-
$10.48 M(-28.0%)
$41.67 M(+75.9%)
Dec 2022
$23.69 M
$14.57 M(-186.2%)
$23.69 M(+654.5%)
Sept 2022
-
-$16.89 M(-150.4%)
$3.14 M(-59.2%)
June 2022
-
$33.51 M(-547.3%)
$7.70 M(-108.9%)
DateAnnualQuarterlyTTM
Mar 2022
-
-$7.49 M(+25.2%)
-$86.64 M(+9.4%)
Dec 2021
-$79.17 M(>+9900.0%)
-$5.98 M(-51.5%)
-$79.17 M(+8.1%)
Sept 2021
-
-$12.34 M(-79.7%)
-$73.21 M(+20.2%)
June 2021
-
-$60.83 M(>+9900.0%)
-$60.92 M(>+9900.0%)
Mar 2021
-
-$19.00 K(-20.8%)
-$93.00 K(+25.7%)
Dec 2020
-$74.00 K(+1750.0%)
-$24.00 K(-44.2%)
-$74.00 K(+48.0%)
Sept 2020
-
-$43.00 K(+514.3%)
-$50.00 K(+614.3%)
June 2020
-
-$7000.00(<-9900.0%)
-$7000.00(<-9900.0%)
Mar 2020
-
$0.00
$0.00
Dec 2019
-$4000.00(<-9900.0%)
-
-
Dec 2018
$0.00
-
-

FAQ

  • What is Spruce Biosciences annual cash flow from investing activities?
  • What is the all time high annual CFI for Spruce Biosciences?
  • What is Spruce Biosciences annual CFI year-on-year change?
  • What is Spruce Biosciences quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for Spruce Biosciences?
  • What is Spruce Biosciences quarterly CFI year-on-year change?
  • What is Spruce Biosciences TTM cash flow from investing activities?
  • What is the all time high TTM CFI for Spruce Biosciences?
  • What is Spruce Biosciences TTM CFI year-on-year change?

What is Spruce Biosciences annual cash flow from investing activities?

The current annual CFI of SPRB is $55.78 M

What is the all time high annual CFI for Spruce Biosciences?

Spruce Biosciences all-time high annual cash flow from investing activities is $55.78 M

What is Spruce Biosciences annual CFI year-on-year change?

Over the past year, SPRB annual cash flow from investing activities has changed by +$32.09 M (+135.43%)

What is Spruce Biosciences quarterly cash flow from investing activities?

The current quarterly CFI of SPRB is $0.00

What is the all time high quarterly CFI for Spruce Biosciences?

Spruce Biosciences all-time high quarterly cash flow from investing activities is $33.51 M

What is Spruce Biosciences quarterly CFI year-on-year change?

Over the past year, SPRB quarterly cash flow from investing activities has changed by -$9.30 M (-100.00%)

What is Spruce Biosciences TTM cash flow from investing activities?

The current TTM CFI of SPRB is $9.30 M

What is the all time high TTM CFI for Spruce Biosciences?

Spruce Biosciences all-time high TTM cash flow from investing activities is $61.05 M

What is Spruce Biosciences TTM CFI year-on-year change?

Over the past year, SPRB TTM cash flow from investing activities has changed by -$46.48 M (-83.33%)